| |
|
|
|
Enlivex Therapeutics Ltd.  
|
|
5.29 0.06 (0.01%) |
07-02 16:00 |
|
Open: |
5.3 |
Pre close: |
5.23 |
Target:
|
7.06
|
|
High: |
5.39 |
Low: |
5.18 |
Resistance:
|
6.04
6.78
|
|
Volume: |
64,190 |
Market Cap: |
71M |
Support:
|
4.85
4.04
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
5.57
 |
MACD |
MACD(12,26):
|
0.03 |
|
MA(20): |
5.76 |
Signal(12,26,9): |
0.13 |
|
MA(100): |
5.73 |
Stochastic Oscillator |
%K(14,3):
|
17.79 |
|
MA(250): |
11.90 |
%D(3): |
30.04 |
|
Average Volume(K) |
3-Month: |
12363
|
52-Week |
High:
|
44.90 |
|
10-Days: |
22916 |
Low: |
3.59 |
|
RSI |
RSI(14):
|
44.10  |
Change(%): |
-75.7 |
|
Financials, Statistics and Valuation |
|
EPS |
-0.730 |
Return on Equity (ttm) |
-33.0 |
Shares Out. (M) |
13.43 |
|
EPS Est. Current Year |
0.000 |
Return on Assets (ttm) |
-18.0 |
Shares Float (M) |
7.31 |
|
EPS Est. Next Year |
0.000 |
PEG Ratio |
0.00 |
% Held by Insiders |
42.08 |
|
EPS Est. Next Quarter |
0.000 |
Qtrly Rev. Growth |
0.0 |
% Held by Institutions |
12.59 |
|
Forward EPS |
-1.400 |
Gross Profit (p.s.) |
0.000 |
Shares Short (K) |
11 |
|
Book Value (p.s.) |
2.390 |
EBITDA (p.s.) |
-0.591 |
P/E |
-7.25 |
|
Sales Per Share |
0.000 |
Qtrly Earnings Growth |
0.00 |
P/BV |
2.21 |
|
Profit Margin |
0.00 |
Operating Cash Flow
(M) |
-5.19 |
P/S |
0.00 |
|
Operating Margin |
0.00 |
Levered Free Cash Flow
(M) |
-3.66 |
P/CF |
-13.69 |
|
|
|
|
|
|
